Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMT-NK plus Pembrolizumab in Advanced Biliary Tract Cancer
NCT05429697Phase 3Recruiting
- Sponsor
- SMT bio Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jan 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 3 trial of SMT-NK in biliary tract cancer (BTC), sponsored by SMT bio Co., Ltd.. Started Jun 2022; status: recruiting.
02
Drugs
SMT-NK
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05429697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429697.